Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study.
Oshima N, Hiraoka S, Hayashi R, Takahashi S, Ishii M, Hashimoto S, Yashima K, Igawa S, Inokuchi T, Ueno Y, Inaba T, Matsumoto H, Kawashima K, Takami T, Isomoto H, Shiotani A, Tanaka S, Ishihara S. Oshima N, et al. Among authors: tanaka s. Inflamm Bowel Dis. 2023 Aug 19:izad150. doi: 10.1093/ibd/izad150. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37598298
Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease.
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Hibi T, et al. Among authors: tanaka s. Inflamm Bowel Dis. 2012 Aug;18(8):1480-7. doi: 10.1002/ibd.21886. Epub 2011 Oct 10. Inflamm Bowel Dis. 2012. PMID: 21987418
Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Hisamatsu T, et al. J Crohns Colitis. 2019 Sep 19;13(9):1097-1104. doi: 10.1093/ecco-jcc/jjz030. J Crohns Colitis. 2019. PMID: 30753377 Clinical Trial.
Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study.
Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Naganuma M, et al. Among authors: tanaka s. J Gastroenterol. 2020 Feb;55(2):169-180. doi: 10.1007/s00535-019-01625-2. Epub 2019 Sep 16. J Gastroenterol. 2020. PMID: 31529220 Clinical Trial.
Endoscopic Lesions of Postoperative Anastomotic Area in Patients With Crohn's Disease in the Biologic Era: A Japanese Multi-Centre Nationwide Cohort Study.
Ueda T, Koyama F, Sugita A, Ikeuchi H, Futami K, Fukushima K, Nezu R, Iijima H, Mizushima T, Itabashi M, Watanabe K, Hata K, Shinagawa T, Matsuoka K, Takenaka K, Sasaki M, Nagayama M, Yamamoto H, Shinozaki M, Fujiya M, Kato J, Ueno Y, Tanaka S, Okita Y, Hashimoto Y, Kobayashi T, Koganei K, Uchino M, Fujii H, Suzuki Y, Hisamatsu T. Ueda T, et al. Among authors: tanaka s. J Crohns Colitis. 2023 Dec 30;17(12):1968-1979. doi: 10.1093/ecco-jcc/jjad116. J Crohns Colitis. 2023. PMID: 37450892
Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
Naganuma M, Kobayashi T, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, Saito D, Nanki K, Narimatsu K, Shiga H, Esaki M, Yoshioka S, Kato S, Saruta M, Tanaka S, Yasutomi E, Yokoyama K, Moriya K, Tsuzuki Y, Ooi M, Fujiya M, Nakazawa A, Abe T, Hisamatsu T; Japanese UC Study Group. Naganuma M, et al. Among authors: tanaka s. J Gastroenterol. 2023 Dec;58(12):1198-1210. doi: 10.1007/s00535-023-02048-w. Epub 2023 Oct 13. J Gastroenterol. 2023. PMID: 37831183
Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.
Naganuma M, Nakamura N, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, Saito D, Kobayashi T, Nanki K, Narimatsu K, Shiga H, Esaki M, Yoshioka S, Kato S, Saruta M, Tanaka S, Yasutomi E, Yokoyama K, Moriya K, Tsuzuki Y, Ooi M, Fujiya M, Nakazawa A, Takagi T, Omori T, Tahara T, Hisamatsu T; Japanese UC Study Group. Naganuma M, et al. Among authors: tanaka s. J Gastroenterol. 2024 Apr;59(4):302-314. doi: 10.1007/s00535-024-02079-x. Epub 2024 Jan 26. J Gastroenterol. 2024. PMID: 38277006
Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Nakase H, et al. Aliment Pharmacol Ther. 2017 Nov;46(9):873-882. doi: 10.1111/apt.14318. Epub 2017 Sep 8. Aliment Pharmacol Ther. 2017. PMID: 28884856 Free PMC article. Clinical Trial.
Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Watanabe K, et al. Clin Gastroenterol Hepatol. 2018 Apr;16(4):542-549.e1. doi: 10.1016/j.cgh.2017.10.036. Epub 2017 Nov 11. Clin Gastroenterol Hepatol. 2018. PMID: 29104132 Free article. Clinical Trial.
13,432 results
You have reached the last available page of results. Please see the User Guide for more information.